Physician profile
Peter Contini
NPI 1346390119
$1,183.47
in general payments reported to CMS, 2019-2025
13 companies · $80.65 in 2025
The $80.65 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $137 · 2021: $86.19 · 2022: $204 · 2023: $287 · 2024: $191 · 2025: $80.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $439.60 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $124.93 | 2019-2022 | |
| Cranial Technologies, INC | $104.65 | 2022-2023 | Doc Band |
| Pfizer INC. | $97.98 | 2019-2024 | |
| Seqirus USA INC | $91.91 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $83.49 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $70.63 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $50.44 | 2021-2023 | Qelbree |
| Alk-Abello, INC | $49.11 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $36.42 | 2024 | Flumist Quadrivalent |
| Dermira, INC. | $16.04 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.06 | 2019 | |
| Organon LLC | $5.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Contini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.